NALO Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 1

NALO Therapeutics General Information

Description

Developer of pharmaceutical products intended to treat hematological and solid tumors. The company's products are small molecule-based medicines for the treatment of cancer and are high-value disease drivers and target major unmet needs in oncology, enabling patients with medicines to treat cancer cells that originate from uncontrolled cellular growth.

Contact Information

Website
www.nalotherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 628 Middlefield Road
  • Palo Alto, CA 94301
  • United States
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 628 Middlefield Road
  • Palo Alto, CA 94301
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NALO Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 01-May-2020 Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view NALO Therapeutics’s complete valuation and funding history, request access »

NALO Therapeutics Patents

  • 6

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 5

    Pending

  • Expiring in next 12 mo

NALO Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021333760-A1 Modulators of myc family proto-oncogene protein Pending 26-Aug-2020
US-20230322722-A1 Modulators of myc family proto-oncogene protein Pending 26-Aug-2020
CA-3190539-A1 Modulators of myc family proto-oncogene protein Pending 26-Aug-2020
EP-4204411-A1 Modulators of myc family proto-oncogene protein Inactive 26-Aug-2020
US-20210369710-A1 Modulators of myc family proto-oncogene protein Pending 19-Feb-2019 A61K31/506
To view NALO Therapeutics’s complete patent history, request access »

NALO Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NALO Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Samsara BioCapital Venture Capital Minority
To view NALO Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

NALO Therapeutics FAQs

  • When was NALO Therapeutics founded?

    NALO Therapeutics was founded in 2017.

  • Where is NALO Therapeutics headquartered?

    NALO Therapeutics is headquartered in Palo Alto, CA.

  • What is the size of NALO Therapeutics?

    NALO Therapeutics has 4 total employees.

  • What industry is NALO Therapeutics in?

    NALO Therapeutics’s primary industry is Drug Discovery.

  • Is NALO Therapeutics a private or public company?

    NALO Therapeutics is a Private company.

  • What is NALO Therapeutics’s current revenue?

    The current revenue for NALO Therapeutics is .

  • Who are NALO Therapeutics’s investors?

    Samsara BioCapital has invested in NALO Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »